International Poster Session12 (JDDW)
October 31, 14:32–15:20, Room 15 (Kobe International Exhibition Hall No.1 Building Digital Poster Venue)
IP-60_H

Protective Effects of Novel Anti-Diabetic Drugs Against MAFLD-Induced Myocardial Injury in an Animal Model

Chun-Chi Yang1,2
Co-authors: Wei-Ting Chang2,3,4, Ming-Lung Yu2,4,5, Yu-Min Ko6
1
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center
2
School of Medicine and Doctoral Program of Clinical and Experimental Medicine, National Sun Yat-sen University
3
Division of Cardiovascular Medicine, Department of Internal Medicine, Chi Mei Medical Center
4
School of Medicine, College of Medicine, and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University
5
Hepatobiliary Division, Department of Internal Medicine, Center of Hepatitis Research, College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University
6
Department of Pharmacy and Master Program, College of Pharmacy and Health Care, Tajen University
We successfully established a MAFLD mouse model that closely mimics the characteristics of human MAFLD. Mice were randomly assigned to five groups: the normal diet (ND) group, the western diet (WD) group, the WD with normal saline vehicle group (WD+NS), the dapagliflozin-treated group (WD+D), and the semaglutide-treated group (WD+S). We investigated the impact of MAFLD on cardiac fibrosis and the protective effects of novel anti-diabetic agents using echocardiography, biochemical analyses, and histological assessments.
Our results demonstrated that MAFLD mice treated with dapagliflozin and semaglutide exhibited improved left ventricular ejection fraction and fractional shortening. These findings suggest that dapagliflozin and semaglutide are promising therapeutic strategies for MAFLD-associated cardiac dysfunction, warranting further investigation.
Page Top